2026-09-21——
AbbVie and Iambic announce multi-year AI drug discovery collaboration in immunology, neuroscience and oncology
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 21 September 2026, AbbVie (NYSE: ABBV) and Iambic announced a multi-year collaboration applying Iambic's AI platform to small molecule drug discovery across immunology, neuroscience and oncology. Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.
What happened
- Announced 21 September 2026 by AbbVie (NYSE: ABBV) and Iambic as a multi-year collaboration across immunology, neuroscience and oncology.
- The collaboration will utilize Enchant v3, Iambic's next-generation multimodal transformer model, trained on over 6,000 molecular properties, along with NeuralPLexer.
- Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated from the collaboration; no dollar figures were disclosed.
- AbbVie full-year 2025 net revenues were $61.160 billion, with immunology at $30.406 billion, neuroscience at $10.767 billion and oncology at $6.655 billion.
Sources
- news.abbvie.com — primary
- news.abbvie.com — party background
- sec.gov — party background
- iambic.ai — party background
- cnbc.com — party background
Announced 2026-09-21 · Added to the register 2026-09-30